Tissue analysis may guide personalized cancer therapy

NCT ID NCT01856296

First seen Aug 10, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study tests whether analyzing a patient's tumor alongside a sample of their normal tissue can help doctors select a more effective treatment for advanced cancer. The approach aims to provide a personalized therapy choice for every participant, even those without known genetic mutations. Researchers will compare how long the chosen treatment controls the cancer versus the previous treatment. The study involves adults with metastatic cancer who can safely undergo a biopsy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Biopsy procedure for molecular analysis
What this could lead to
If successful, this approach could help doctors choose more effective, personalized treatments for people with advanced cancer, potentially improving survival.
What could go wrong
This is an early-stage exploratory study, and the benefit of this biopsy-guided approach is not yet proven. It may not work for all patients or cancer types, and biopsies carry risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institut Gustave Roussy

    Villejuif, Val de Marne, 94805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.